oncology
Lung Cancer

Adding ErbB-TKI to KRAS inhibitor may help circumvent lung cancer resistance

Combining a pan-ErbB tyrosine kinase inhibitor, afatinib, with the KRAS inhibitor sotorasib appears feasible in treating non-small cell lung cancer (NSCLC) patients with mutated KRAS whose disease had progressed on prior therapies, including KRAS inhibitor monotherapy, a US study suggests. Interim results from the phase Ib study CodeBreaK 101 provide proof of principle for the ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic